Tomorrow Investor

The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)

Vancouver, British Columbia–(Newsfile Corp. – May 21, 2026) – The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the “Company” or “Precision”), a publicly traded wellness company building a platform for high quality peptide formulations, today provides additional detail on its previously announced Exclusive Strategic Marketing Agreement (the “Agreement”) with Mixed Martial Arts Group Limited (“MMA”), and outlines the strategic significance of the partnership for the Company’s commercialization roadmap. A Differentiated Channel Into the Global Combat Sports Community Under the Agreement, Precision has secured exclusive marketing rights across MMA.INC’s digitally connected combat sports ecosystem, which the Company believes represents a highly engaged, performance driven and recovery-focused consumer demographic.

This excerpt is quoted from the original release. Read the full announcement on Newsfile Corp.

Brief Summary

The Precision Peptide Company (BPC) has announced an exclusive strategic partnership with MMA.INC to access their vast global combat sports ecosystem.

  • Direct commercial access to over 5M+ social media followers.
  • The partnership features a 50/50 revenue share in the first year, shifting to 75/25 thereafter.
  • Precision products are U.S. manufactured and third-party tested, ensuring compliance.
  • New vertical targets an engaged athletic community.

Why it matters: This partnership positions BPC strongly within a lucrative and passionate consumer space, paving the way for enhanced growth.

Read the Full Article

This is a summary of the press release. For the complete article and any additional details, please visit the original source.

Read Full Article

Attribution: Original press release by Newsfile Corp on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.

Tomorrow Investor
The Tomorrow Investor

Markets research for retail investors

Independent coverage of small-cap equities, biotech catalysts, and emerging market opportunities.